172 related articles for article (PubMed ID: 38050021)
1. Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
Hernandez KM; Venkat A; Elbers DC; Bihn JR; Brophy MT; Do NV; La J; Liu Q; Prokhorenkov A; Metoki-Shlubsky N; Sung FC; Paller CJ; Fillmore NR; Grossman RL
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050021
[TBL] [Abstract][Full Text] [Related]
2. Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.
Valle LF; Nickols NG; Hausler R; Alba PR; Anglin-Foote T; Perez C; Yamoah K; Rose BS; Kelley MJ; DuVall SL; Garraway IP; Maxwell KN; Lynch JA
Oncologist; 2023 Jun; 28(6):e473-e477. PubMed ID: 37084789
[TBL] [Abstract][Full Text] [Related]
3. The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology.
Do N; Grossman R; Feldman T; Fillmore N; Elbers D; Tuck D; Dhond R; Selva L; Meng F; Fitzsimons M; Ajjarapu S; Ayandeh S; Hall R; Do S; Brophy M
Semin Oncol; 2019; 46(4-5):314-320. PubMed ID: 31629530
[TBL] [Abstract][Full Text] [Related]
4. External validation of a prognostic model for mortality among patients with non-small-cell lung cancer using the Veterans Precision Oncology Data Commons.
Cheng D; Ramos-Cejudo J; Tuck D; Elbers D; Brophy M; Do N; Fillmore N
Semin Oncol; 2019; 46(4-5):327-333. PubMed ID: 31708233
[TBL] [Abstract][Full Text] [Related]
5. Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program.
Doerstling S; Winski D; Katsoulakis E; Agarwal P; Poonnen PJ; Snowdon JL; Jackson GP; Weeraratne D; Kelley MJ; Vashistha V
J Cancer Res Clin Oncol; 2023 Jan; 149(1):69-77. PubMed ID: 36117189
[TBL] [Abstract][Full Text] [Related]
6. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
7. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.
Armstrong AJ; Li X; Tucker M; Li S; Mu XJ; Eng KW; Sboner A; Rubin M; Gerstein M
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):786-793. PubMed ID: 33568750
[TBL] [Abstract][Full Text] [Related]
8. The Veterans Affairs Precision Oncology Data Repository, a Clinical, Genomic, and Imaging Research Database.
Elbers DC; Fillmore NR; Sung FC; Ganas SS; Prokhorenkov A; Meyer C; Hall RB; Ajjarapu SJ; Chen DC; Meng F; Grossman RL; Brophy MT; Do NV
Patterns (N Y); 2020 Sep; 1(6):100083. PubMed ID: 33205130
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
12. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
13. The mutational landscape of prostate cancer.
Barbieri CE; Bangma CH; Bjartell A; Catto JW; Culig Z; Grönberg H; Luo J; Visakorpi T; Rubin MA
Eur Urol; 2013 Oct; 64(4):567-76. PubMed ID: 23759327
[TBL] [Abstract][Full Text] [Related]
14. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
15. Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program.
Poonnen PJ; Duffy JE; Hintze B; Shukla M; Brettin TS; Conrad NR; Yoo H; Guertin C; Looney JA; Vashistha V; Kelley MJ; Spector NL
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914016
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
17. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
18. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G; Ravindranathan D; Graham LS; Sokolova A; Tripathi A; Pilling A; Jindal T; Ravindra A; Cackowski FC; Sweeney PL; Thapa B; Amery TS; Heath EI; Garje R; Zakharia Y; Koshkin VS; Bilen MA; Schweizer MT; Barata PC; Dorff TB; Cieslik M; Alva AS; Armstrong AJ
JCO Precis Oncol; 2024 Apr; 8():e2300567. PubMed ID: 38579192
[TBL] [Abstract][Full Text] [Related]
19. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Linch M; Goh G; Hiley C; Shanmugabavan Y; McGranahan N; Rowan A; Wong YNS; King H; Furness A; Freeman A; Linares J; Akarca A; Herrero J; Rosenthal R; Harder N; Schmidt G; Wilson GA; Birkbak NJ; Mitter R; Dentro S; Cathcart P; Arya M; Johnston E; Scott R; Hung M; Emberton M; Attard G; Szallasi Z; Punwani S; Quezada SA; Marafioti T; Gerlinger M; Ahmed HU; Swanton C
Ann Oncol; 2017 Oct; 28(10):2472-2480. PubMed ID: 28961847
[TBL] [Abstract][Full Text] [Related]
20. Genetic mutations in smoking-associated prostate cancer.
Elshafei A; Al-Toubat M; Feibus AH; Koul K; Jazayeri SB; Lelani N; Henry V; Balaji KC
Prostate; 2023 Sep; 83(13):1229-1237. PubMed ID: 37455402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
